MX2018009506A - Vacunas contra el cáncer y métodos de tratamiento que las utilizan. - Google Patents

Vacunas contra el cáncer y métodos de tratamiento que las utilizan.

Info

Publication number
MX2018009506A
MX2018009506A MX2018009506A MX2018009506A MX2018009506A MX 2018009506 A MX2018009506 A MX 2018009506A MX 2018009506 A MX2018009506 A MX 2018009506A MX 2018009506 A MX2018009506 A MX 2018009506A MX 2018009506 A MX2018009506 A MX 2018009506A
Authority
MX
Mexico
Prior art keywords
methods
treatment
same
cancer vaccines
vaccine
Prior art date
Application number
MX2018009506A
Other languages
English (en)
Spanish (es)
Inventor
Yan Jian
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of MX2018009506A publication Critical patent/MX2018009506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2018009506A 2016-02-05 2017-02-03 Vacunas contra el cáncer y métodos de tratamiento que las utilizan. MX2018009506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291601P 2016-02-05 2016-02-05
PCT/US2017/016557 WO2017136758A1 (en) 2016-02-05 2017-02-03 Cancer vaccines and methods of treatment using the same

Publications (1)

Publication Number Publication Date
MX2018009506A true MX2018009506A (es) 2019-05-06

Family

ID=59500919

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009506A MX2018009506A (es) 2016-02-05 2017-02-03 Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
MX2023001540A MX2023001540A (es) 2016-02-05 2018-08-03 Vacunas contra el cancer y metodos de tratamiento que las utilizan.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001540A MX2023001540A (es) 2016-02-05 2018-08-03 Vacunas contra el cancer y metodos de tratamiento que las utilizan.

Country Status (10)

Country Link
US (4) US11007255B2 (enExample)
EP (1) EP3411122A4 (enExample)
JP (1) JP7123800B2 (enExample)
KR (2) KR102742526B1 (enExample)
CN (2) CN108883312B (enExample)
AU (1) AU2017214656B2 (enExample)
BR (1) BR112018015893A2 (enExample)
CA (1) CA3013718C (enExample)
MX (2) MX2018009506A (enExample)
WO (1) WO2017136758A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017214656B2 (en) * 2016-02-05 2022-08-25 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
US20200147195A1 (en) * 2017-05-26 2020-05-14 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
CA3080835A1 (en) 2017-10-31 2019-05-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
EP3723798A4 (en) 2017-12-13 2021-11-17 Inovio Pharmaceuticals, Inc. CANCER VACCINES TARGETING BORIS AND RELATED USES
UA128236C2 (uk) 2018-12-21 2024-05-15 Айоніс Фармасутікалз, Інк. Модулятори експресії hsd17b13
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
US20250026818A1 (en) 2021-10-19 2025-01-23 Sciencemed Spóka z ograniczon odpowiedzialnoci Male contraception
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
PT681483E (pt) 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
JP2003505114A (ja) 1998-07-13 2003-02-12 ジェネトロニクス、インコーポレーテッド パルス電場による皮膚および筋肉を標的とした遺伝子治療
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
KR101710981B1 (ko) * 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
ES2993941T3 (en) 2006-10-17 2025-01-14 Inovio Pharmaceuticals Inc Electroporation devices for electroporation of cells in mammals
WO2008148010A1 (en) 2007-05-23 2008-12-04 Vgx Pharmaceuticals, Inc. Composition comprising high concentration of biologically active molecules and processes for preparing the same
WO2013019603A2 (en) * 2011-07-29 2013-02-07 Inovio Pharmaceuticals, Inc. Linear expression cassettes and uses thereof
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
WO2014154905A1 (en) * 2013-03-28 2014-10-02 Invectys A cancer vaccine for dogs
WO2015023461A2 (en) * 2013-08-06 2015-02-19 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
AU2017214656B2 (en) * 2016-02-05 2022-08-25 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
US20200147195A1 (en) 2017-05-26 2020-05-14 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same

Also Published As

Publication number Publication date
MX2023001540A (es) 2023-03-08
JP2019508403A (ja) 2019-03-28
WO2017136758A1 (en) 2017-08-10
KR102742526B1 (ko) 2024-12-18
CN108883312A (zh) 2018-11-23
JP7123800B2 (ja) 2022-08-23
CN108883312B (zh) 2024-04-09
KR20250002803A (ko) 2025-01-07
KR20180108793A (ko) 2018-10-04
EP3411122A1 (en) 2018-12-12
CA3013718C (en) 2023-09-26
CN118184761A (zh) 2024-06-14
US20210268084A1 (en) 2021-09-02
AU2017214656A1 (en) 2018-08-30
US20250319178A1 (en) 2025-10-16
US20240082374A1 (en) 2024-03-14
BR112018015893A2 (pt) 2019-03-06
EP3411122A4 (en) 2019-10-23
US20190038729A1 (en) 2019-02-07
AU2017214656B2 (en) 2022-08-25
AU2022271441A1 (en) 2022-12-22
US11007255B2 (en) 2021-05-18
US11801288B2 (en) 2023-10-31
CA3013718A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
MX2018009506A (es) Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2022007522A (es) Anticuerpos anti-cd27.
MX2023014569A (es) Anticuerpos anti-sirpa.
NZ746755A (en) Anti-tim-3 antibodies and compositions
EA201800148A1 (ru) Оспенная вакцина для лечения рака
MX2017005325A (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2018002166A (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
EP4043031A3 (en) Zika viral antigen constructs
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
CL2017000625A1 (es) Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2020004376A (es) Uso de inhibidores de nox para el tratamiento de cancer.
MX2022009171A (es) Composiciones para el tratamiento de dermatitis atopica canina y sus usos.